Advanced Solutions
for Advanced Pathology
PMS2 (MRQ-28)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45253 IMPATH PMS2 RTU M (MRQ-28)
50 Tests
44372 PMS2 RTU M (MRQ-28)
7 ml Ready To Use
44763 PMS2 0,1 M (MRQ-28)
100 µl liquid Concentrated
44764 PMS2 1 M (MRQ-28)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
Colon
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP 2-step Polymer (Universal) or AP
2-step Polymer (Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Microsatellite instability (MSI) is characterized by genome-wide alterations in short, repetitive DNA sequences. It is caused by defects in the
nucleotide mismatch repair (MMR) system. Biologically, defective MMR results in a general increase in the mutation rate and the development
of a “mutator phenotype.”
In colorectal cancer (CRC), high-level MSI was first described in tumors from patients with hereditary non-polyposis colorectal cancer (HNPCC).
In about 70% of cases, the HNPCC syndrome develops as a result of an inherited germline mutation of one allele, followed by a somatic mutation
of the other allele in one of several mismatch repair genes: hMSH2, hMLH1, hPMS1, hPMS2, hMSH6, and hMLH3. Ninety-five percent of the
mutations occur in hMSH2 or hMLH1.
Most colorectal carcinomas are thought to be of the chromosomal instable (CIN) or microsatellite stable (MSS) genotype. However, approximately
15% are thought to be of the MSI genotype, of which the HNPCC cases represent less than one-third. The MSS and MSI tumors also seem
to differ in clinicopathologic features. The MSI tumors are more often located in the proximal colon and may be synchronous. On histologic
examination, they are more often mucinous or poorly differentiated. The patients with MSI-type colorectal carcinomas are generally thought to
have a better prognosis than patients with MSS-type colorectal carcinomas. On the other hand, MSS tumors are more often located in the distal
colon and represent typical adenocarcinomas. Although the results published so far have been conflicting, some studies suggest that patients
with MSI-type colorectal carcinomas seem to have a greater benefit from adjuvant chemotherapy than patients with MSS-type colorectal
carcinomas.
Microsatellite Instability
PMS2
MLH1
MSH2
MSH6
Mismatch Repair Mutations
-
+
+
+
Reference
1. Chen JR, et al. Br J Surg. 2008 Jan; 95(1):102-10.
2. de Jong AE, et al. Clin Cancer Res. 2004 Feb 1; 10(3):972-80.
3. Fallik D, et al. Cancer Res. 2003 Sep 15; 63(18):5738-44.
4. Gill S, et al. Clin Cancer Res. 2005 Sep 15; 11(18):6466-71.
203
